Ocular Therapeutix, Inc.
Clinical trials sponsored by Ocular Therapeutix, Inc., explained in plain language.
Biopharmaceutical company developing therapies for eye diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye implant could slow vision loss in diabetes Results expected Mar 2027 (estimated) 🚀 Make-or-break
-
New eye implant shows promise for Long-Term wet AMD control
Disease control Recruiting nowThis study is checking the long-term safety of an implant called OTX-TKI (axitinib) for people with wet age-related macular degeneration (AMD). The implant is placed in the eye and slowly releases medicine to control the disease. About 850 people who already completed two years o…
Phase 3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New eye implant could slow vision loss in diabetes
Disease control Recruiting nowThis Phase 3 trial tests an implant called OTX-TKI that slowly releases the drug axitinib inside the eye. It aims to stop or slow worsening of non-proliferative diabetic retinopathy, a common diabetes complication that can lead to vision loss. About 930 adults with moderate to se…
Phase 3 • Sponsor: Ocular Therapeutix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC